ArticleAnnals of hematology2024

MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

Stefanie Jilg et al.PubMed ↗Publisher ↗

No numbers read from the abstract.